DOCSLIB.ORG

Decentralised Procedures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Decentralised Procedures SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT <Product name> 100 mg capsules, hard 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule, hard contains 100 mg racecadotril. Excipient(s) with known effect: Each capsule, hard contains 41 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Capsule, hard Ivory-coloured capsules, hard, capsule size no. 2, containing a white powder with a sulphurous odour. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications <Product name> is indicated for the symptomatic treatment of acute diarrhoea in adults over 18 years when specific treatment is not possible. If specific treatment is possible, racecadotril can be given as adjunctive treatment. 4.2 Posology and method of administration Posology Adults 1 capsule 3 times daily, preferably before main meals. On the first day of treatment, one additional capsule should be taken initially, regardless of the time of day. Treatment should be continued until 2 normal stools have been passed; however, the duration of treatment should not exceed 3 days. Long-term treatment with racecadotril is not recommended. Paediatric population Special formulations of racecadotril are available for infants, children and adolescents. Elderly population No dose adjustment is necessary in elderly patients. Caution is required in patients with renal or hepatic impairment (see section 5.2). Method of administration Oral use. 4.3 Contraindications 2 Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. <Product name> is contraindicated in diarrhoea associated with fever and/or bloody or purulent stools as this may indicate the presence of invasive bacteria or other serious diseases. Medical advice should be sought in these cases. <Product name> is contraindicated in antibiotic-associated diarrhoea (pseudomembranous colitis). <Product name> is contraindicated in patients who experienced angioedema while under treatment with ACE inhibitors (e.g. captopril, enalapril, lisinopril, perindopril, ramipril). 4.4 Special warnings and precautions for use Precautions for use The use of <Product name> does not modify the usual rehydration regimens. Medical advice should be sought in the event of an acute episode of ulcerative colitis. There are limited data in patients with renal or hepatic impairment. Special care is required when treating these patients and <Product name> must not be used unless prescribed by a doctor (see section 5.2). The availability of the active substance may be reduced in patients with persistent vomiting. In case of chronic diarrhoea, a medical doctor should be consulted. Warning This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. Occurrence of skin reactions has been reported with the use of the product. These are in most cases mild and do not require treatment but in some cases they can be severe, even life- threatening (Stevens-Johnson syndrome, toxic epidermal necrolysis, skin exfoliation, DRESS). Association with racecadotril cannot be fully excluded. When experiencing severe skin reactions (e.g. progressive skin rash often with blisters or mucosal lesions), the treatment has to be stopped immediately. Patients should be advised of the signs and symptoms and monitored closely for skin reactions. 4.5 Interaction with other medicinal products and other forms of interaction ACE inhibitors (e.g. captopril, enalapril, lisinopril, perindopril, ramipril) are known to cause angioedema. This risk may be elevated when used concomitantly with <product name> against acute diarrhoea. Co-administration of racecadotril with loperamide or nifuroxazide does not modify the kinetics of racecadotril in man. 4.6 Fertility, pregnancy and lactation Pregnancy There are no adequate data from the use of racecadotril in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, fertility, embryonal/foetal development, childbirth/delivery or postnatal development (see section 5.3). As 3 no specific clinical studies are available, however, <Product name> should not be used in pregnant women. Breastfeeding This medicinal product should not be used in breast-feeding women because of a lack of information regarding passage of the active substance into breast milk. Fertility No effects on fertility were observed in fertility studies carried out with racecadotril in rats. 4.7 Effects on ability to drive and use machines <Product name> has no or negligible influence on the ability to drive and use machines. 4.8 Undesirable effects Data from clinical studies in acute diarrhoea patients are available for 2193 adults treated with racecadotril and 282 treated with placebo. The undesirable effects listed below have occurred more frequently with racecadotril than with placebo or have been reported during postmarketing surveillance. The frequency of undesirable effects is defined using the following convention: Very common 1/10 Common 1/100 to < 1/10 Uncommon 1/1,000 to < 1/100 Rare 1/10,000 to < 1/1,000 Very rare < 1/10,000 Not known cannot be estimated from the available data Nervous system disorders Common: Headache Skin and subcutaneous tissue disorders (see section 4.4) Uncommon: Rash, erythema Not known: Erythema multiforme, tongue oedema, facial oedema, lip oedema, eyelid oedema, angioedema, urticaria, erythema nodosum, papular rash, prurigo, pruritus, toxic skin eruption Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. 4.9 Overdose No cases of overdose have been reported. In adults, single doses above 2 g (equivalent to 20 times the therapeutic dose) have not had any harmful effects. 5. PHARMACOLOGICAL PROPERTIES 5.1 Pharmacodynamic properties 4 Pharmacotherapeutic group: Other antidiarrheals ATC code: A07XA04 Racecadotril is a prodrug which is hydrolysed to its active metabolite thiorphan. Thiorphan is an inhibitor of enkephalinase, a cell membrane peptidase located in various tissues, notably the epithelium of the small intestine. This enzyme contributes both to the hydrolysis of exogenous peptides and to the breakdown of endogenous peptides such as enkephalins. Racecadotril protects enkephalins from enzymatic breakdown (which is increased in acute diarrhoea), prolonging their action at enkephalinergic synapses in the small intestine and reducing hypersecretion without affecting basal secretion. Racecadotril is a pure intestinal antisecretory active substance. It reduces intestinal hypersecretion of water and electrolytes induced by cholera toxins or inflammation and does not affect basal secretory activity. By potentiating the action of enkephalins on delta-opioid receptors, it exerts a rapid antidiarrhoeal effect without modifying intestinal transit. Racecadotril does not produce abdominal distension or increased abdominal wall tension. During clinical development, the incidence of secondary constipation was comparable in patients treated with racecadotril and patients treated with placebo. Following oral administration, racecadotril has exclusively peripheral activity, with no effects on the central nervous system. In randomised, double-blind active comparator studies carried out in patients with acute diarrhoea, the antisecretory agent racecadotril and the antimotility agent loperamide were found to be equally effective with respect to onset of action, reduction of stool frequency and duration of diarrhoea. A randomised crossover study showed that, when given at therapeutic doses (1 capsule) or supratherapeutic doses (4 capsules), racecadotril 100 mg capsules (<Product name>) did not induce QT/QTc prolongation in 56 healthy subjects (unlike moxifloxacin, which was used as a positive control). 5.2 Pharmacokinetic properties Absorption Following oral administration, racecadotril is rapidly absorbed. The bioavailability of racecadotril is not modified by food but peak activity is delayed by about 1½ hours. Distribution Following oral administration of 14C-labelled racecadotril in healthy subjects, levels of racecadotril in plasma were more than 200 times higher than in blood cells and 3 times higher than in whole blood. The drug therefore did not bind to blood cells to any significant extent. Distribution of radioactivity in other tissues was moderate, as indicated by a mean apparent volume of distribution in plasma of 66.4 kg. 90% of the active metabolite of racecadotril, thiorphan ((RS)-N-(1-oxo-2-(mercaptomethyl)-3- phenylpropyl)glycine), is bound to plasma proteins, mainly to albumin. Biotransformation The half-life of racecadotril, measured as plasma enkephalinase inhibition, is about 3 hours. Racecadotril is rapidly hydrolysed to its active metabolite, thiorphan ((RS)-N-(1-oxo-2- (mercaptomethyl)-3-phenylpropyl)glycine), which is in turn transformed into inactive 5 metabolites, identified as S-methylthiorphan sulphoxide, S-methylthiorphan, 2- methanesulphinylmethyl propionic acid and 2-methylsulphanylmethyl propionic acid. Each of these metabolites exceeds 10% of the systemic exposure to the parent drug. Additional minor metabolites were also detected and quantified
Load more

Recommended publications
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Racecadotril in the Treatment of Acute Diarrhea in Children
    Eberlin et al. BMC Pediatrics (2018) 18:124 https://doi.org/10.1186/s12887-018-1095-x RESEARCH ARTICLE Open Access Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials Marion Eberlin1, Min Chen2, Tobias Mueck1 and Jan Däbritz3,4* Abstract Background: Racecadotril is a guideline-recommended option for the treatment of acute diarrhea in children but existing guidelines and previous reviews of the field are based on a small fraction of published evidence. Therefore, we have performed a systematic search for randomized controlled trials evaluating racecadotril as add-on or in comparison to other treatments. Methods: A search was performed in PubMed, Scopus and Google Scholar without limits about country of origin or reporting language. A meta-analysis was conducted for the five most frequently used efficacy parameters. Results: We have retrieved 58 trials, from nine countries including six in comparison to placebo, 15 in comparison to various active treatments and 41 as add-on to various standard treatments (some multi-armed studies allowing more than one comparison). Trials used 45 distinct efficacy parameters, most often time to cure, % of cured children after 3 days of treatment, global efficacy and number of stools on second day of treatment. Racecadotril was superior to comparator treatments in outpatients and hospitalized patients with a high degree of consistency as confirmed by meta-analysis for the five most frequently used outcome parameters. For instance, it reduced time to cure from 106.2 h to 78.2 h (mean reduction 28.0 h; P < 0.0001 in 24 studies reporting on this parameter).
    [Show full text]
  • A D O L E S C E N
    92739 285-299 23/05/06 16:27 Page 285 VOLUME 26 २ NUMERO 5 MAI 2006 २ CAHIER 2 ADOLESCENCE La diarrhée du nourrisson. De la toxicose à la gastroentérite aiguë : une vieille histoire २ La diarrhée aiguë : un symptôme piège ? २ Diarrhée aiguë du nourrisson : critères de gravité २ Diarrhée aiguë du jeune enfant : quelle mortalité aujourd’hui en France ? २ Le syndrome hémolytique et urémique : toujours l’avoir à l’esprit २ La diarrhée aiguë en crèche : prévention, éviction २ Vaccination antirotavirus: des développements attendus २ Soluté de réhydratation orale : du concept à la commercialisation २ Les conseils à l’officine २ Faut-il bouder le régime antidiarrhéique ? २ Les médicaments antidiarrhéiques २ Antibiotiques et diarrhée aiguë en zone tempérée २ Diarrhée du retour : une entité spécifique ? २ Une campagne régionale d’information et d’éducation des familles २ Doit-on actualiser nos recommandations ? e ISSN 0291-0233 Compte rendu de la 4 Journée du groupe de pédiatrie générale de la Société française de pédiatrie. 92739 285-299 19/05/06 18:57 Page 286 Cahier 2, volume 26, numéro 5, de Médecine & enfance, revue mensuelle répertoriée dans la banque de données CNRS/PASCAL de l’INIST, éditée par Edition et communication médicales, membre du Syndicat national de la presse médicale et des professions de santé. SARL au capital de 7622,45 euros. 23, rue Saint-Ferdinand, 75017 Paris. Tél. : 01.45.74.44.65. Fax : 01.40.55.94.13. RC Paris B 321 539 447. Revue hors commerce, réservée exclusivement au corps médical. Copyright Edition et communication médicales 2006.
    [Show full text]
  • World Journal of Pharmaceutical Research Yashasvi Et Al
    World Journal of Pharmaceutical Research Yashasvi et al . World Journal of Pharmaceutical SJIF Research Impact Factor 6.805 Volume 6, Issue 1, 998-1004. Research Article ISSN 2277– 7105 EFFICACY OF RACECADOTRIL COMPARED TO DIPHENOXYLATE IN ACUTE RADIATION ENTERITIS Dr. Yashasvi Suvarna*, Dr. Janaki M. G. and Dr. M. C. Shivamurthy Departments of Pharmacology and Radiation Oncology, M S Ramaiah Medical College and Hospitals, Bangalore. ABSTRACT Article Received on 08 Nov. 2016, Introduction: Radiation enteritis is one of the most common and Revised on 28 Nov. 2016, distressing complications of pelvic radiation. There are limited studies Accepted on 18 Dec. 2016 DOI: 10.20959/wjpr20171-7629 that have assessed the efficacy of antidiarrhoeals in radiation enteritis. This study was done to assess the efficacy of racecadotril versus diphenoxylate in acute radiation enteritis. Methods: This was a *Corresponding Author Dr. Yashasvi Suvarna prospective open label randomized study.50 patients were recruited Departments of into the study with 25 patients in each group. They received either Tab. Pharmacology and Racecadotril 100mg tid for 3 days or Tab. Diphenoxylate Radiation Oncology, M S Hydrochloride 2.5 mg(+ atropine 0.025 mg) tid for 3 days as an add on Ramaiah Medical College and Hospitals, Bangalore. to fluid supplementation. Results: The grade of radiation enteritis in both the groups were similar after 3 days of treatment with the drug (p=0.210).Only one patient in the racecadotril group required cessation of pelvic radiation due to hypokalemia. Conclusion: Racecadotril and diphenoxylate are both effective in treating radiation enteritis and are well tolerated. Further studies with racecadotril are warranted.
    [Show full text]
  • The Private Sector Market for Diarrhea Treatment in India
    The Private Sector Market for Diarrhea Treatment in India April 2012 Clinton Health Access Initiative New Delhi, India Table of Contents Abbreviations ..........................................................................................................................................................................3 Acknowledgments..................................................................................................................................................................4 Executive Summary ..............................................................................................................................................................5 Context .......................................................................................................................................................................................8 Methodology ............................................................................................................................................................................9 Diarrhea Treatment Private Sector Supply Chain.................................................................................................... 11 Regulatory Environment .................................................................................................................................................. 16 Manufacturing .....................................................................................................................................................................
    [Show full text]
  • Stoffwechsel- Und Verdauungsstörungen Verdauungsstörungen Stoffwechsel- Und Siegfried Sulzenbacher Naturheilkundliche Praxis Behandlungskonzepte Fürdie LESEPROBE
    Behandlungskonzepte für die naturheilkundliche Praxis Siegfried Sulzenbacher Stoffwechsel- und Verdauungsstörungen LESEPROBE Stoffwechsel- und Verdauungsstörungen Siegfried Sulzenbacher Stoffwechsel- und Verdauungsstörungen Siegfried Sulzenbacher Wichtige Hinweise: Das vorliegende Buch wurde sorgfältig erarbeitet. Alle Angaben erfolgen jedoch ohne Gewähr. Weder der Autor noch der Verlag haften für eventuelle Nachteile oder Schäden, die möglicherweise aus der Anwendung der nachfolgenden Hinweise und Therapieempfehlungen resultieren könnten. Da jeder Patient anders ist, kann Dosierung und Indikation nicht allgemein verbindlich festgelegt werden. Dies ist die ausschließliche Verant- wortung des Behandlers gegenüber seinem Patienten. Die aufgeführten Präparatenamen sind lediglich Beispiele, die der Praxiserfahrung des Autors entsprechen. Es bedeutet nicht, dass nicht auch mit anderen Präparaten gute Ergebnisse erzielt werden können. 1. Auflage 2020 © 2020 ML Verlag in der Mediengruppe Oberfranken – Fachverlage GmbH & Co. KG, Kulmbach Druck: Generál Nyomda Kft., H-6727 Szeged Das Werk einschließlich aller seiner Teile ist urheberrechtlich geschützt. Vervielfältigung, Übersetzung, Mikroverfilmung und Einspeicherung und Verarbeitung in elektronische Systeme ist unzulässig und strafbar. Lektorat: Martin Klose Titelbild: © Romolo Tavani – stock.adobe.com www.ml-buchverlag.de ISBN: 978-3-96474-201-8 Inhaltsverzeichnis Vorwort .......................................................... 9 Einführung ........................................................11
    [Show full text]
  • Acute Diarrhea in Adults WENDY BARR, MD, MPH, MSCE, and ANDREW SMITH, MD Lawrence Family Medicine Residency, Lawrence, Massachusetts
    Acute Diarrhea in Adults WENDY BARR, MD, MPH, MSCE, and ANDREW SMITH, MD Lawrence Family Medicine Residency, Lawrence, Massachusetts Acute diarrhea in adults is a common problem encountered by family physicians. The most common etiology is viral gastroenteritis, a self-limited disease. Increases in travel, comorbidities, and foodborne illness lead to more bacteria- related cases of acute diarrhea. A history and physical examination evaluating for risk factors and signs of inflammatory diarrhea and/or severe dehydration can direct any needed testing and treatment. Most patients do not require labora- tory workup, and routine stool cultures are not recommended. Treatment focuses on preventing and treating dehydra- tion. Diagnostic investigation should be reserved for patients with severe dehydration or illness, persistent fever, bloody stool, or immunosuppression, and for cases of suspected nosocomial infection or outbreak. Oral rehydration therapy with early refeeding is the preferred treatment for dehydration. Antimotility agents should be avoided in patients with bloody diarrhea, but loperamide/simethicone may improve symptoms in patients with watery diarrhea. Probiotic use may shorten the duration of illness. When used appropriately, antibiotics are effective in the treatment of shigellosis, campylobacteriosis, Clostridium difficile,traveler’s diarrhea, and protozoal infections. Prevention of acute diarrhea is promoted through adequate hand washing, safe food preparation, access to clean water, and vaccinations. (Am Fam Physician. 2014;89(3):180-189. Copyright © 2014 American Academy of Family Physicians.) CME This clinical content cute diarrhea is defined as stool with compares noninflammatory and inflamma- conforms to AAFP criteria increased water content, volume, or tory acute infectious diarrhea.7,8 for continuing medical education (CME).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau Et Al
    US 20150202317A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0202317 A1 Rau et al. (43) Pub. Date: Jul. 23, 2015 (54) DIPEPTDE-BASED PRODRUG LINKERS Publication Classification FOR ALPHATIC AMNE-CONTAINING DRUGS (51) Int. Cl. A647/48 (2006.01) (71) Applicant: Ascendis Pharma A/S, Hellerup (DK) A638/26 (2006.01) A6M5/9 (2006.01) (72) Inventors: Harald Rau, Heidelberg (DE); Torben A 6LX3/553 (2006.01) Le?mann, Neustadt an der Weinstrasse (52) U.S. Cl. (DE) CPC ......... A61K 47/48338 (2013.01); A61 K3I/553 (2013.01); A61 K38/26 (2013.01); A61 K (21) Appl. No.: 14/674,928 47/48215 (2013.01); A61M 5/19 (2013.01) (22) Filed: Mar. 31, 2015 (57) ABSTRACT The present invention relates to a prodrug or a pharmaceuti Related U.S. Application Data cally acceptable salt thereof, comprising a drug linker conju (63) Continuation of application No. 13/574,092, filed on gate D-L, wherein D being a biologically active moiety con Oct. 15, 2012, filed as application No. PCT/EP2011/ taining an aliphatic amine group is conjugated to one or more 050821 on Jan. 21, 2011. polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeu (30) Foreign Application Priority Data tically useful half-lives. The invention also relates to pharma ceutical compositions comprising said prodrugs and their use Jan. 22, 2010 (EP) ................................ 10 151564.1 as medicaments. US 2015/0202317 A1 Jul. 23, 2015 DIPEPTDE-BASED PRODRUG LINKERS 0007 Alternatively, the drugs may be conjugated to a car FOR ALPHATIC AMNE-CONTAINING rier through permanent covalent bonds.
    [Show full text]
  • Racecadotril in the Management of Rotavirus and Non-Rotavirus Diarrhea in Under-Five Children: Two Randomized, Double-Blind, Placebo-Controlled Trials
    R E S E A R C H P A P E R Racecadotril in the Management of Rotavirus and Non-rotavirus Diarrhea in Under-five Children: Two Randomized, Double-blind, Placebo-controlled Trials GAGANDEEP KANG, SOWMYANARAYANAN V THUPPAL, RAJAN SRINIVASAN, RAJIV SARKAR, BEULA SUBASHINI, SRINIVASAN VENUGOPAL, KULANDAIPALAYAM SINDHU, DHIVYA A NBU, *NATHALIE PAREZ, #LENNART SVENSSON AND $ANURADHA BOSE From the Departments of Gastrointestinal Sciences, Christian Medical College, Vellore, India; *Service des Urgences Pédiatriques, Hôpital d’enfants Armand Trousseau, Assistance Publique-Hôpitaux de Paris, Paris, France; #Division of Molecular Virology, Department of Clinical and Experimental Medicine, Medical Faculty, Linko ping University, Linko ping, Sweden; and $Community Health, Christian Medical College, Vellore, India. Correspondence to: Dr. Gagandeep Kang, Professor and Head, Division of Gastrointestinal Sciences, Christian Medical College, Vellore, India. [email protected] Received: July 06, 2015; Initial review: September 26, 2015; Accepted: May 07, 2016. Objective: To study the effect of racecadotril on reduction in the median total stool weight was 74 g/kg and 53.5 g/kg in duration of acute rotavirus and non-rotavirus diarrhea. racecadotril group and placebo group, respectively (P=0.4); and Design: Two randomized double-blind placebo-controlled trials average fluid intake per day was 3.6 mL/kg/h and 3mL/kg/h in racecadotril and placebo arms, respectively (P=0.3). Among Setting: Community-based trial in an urban area in Vellore, rotavirus-positive children, median duration of diarrhea was 26.9 hospital-based trial at a secondary hospital in Vellore h and 30.2 h in racecadotril and placebo arms, respectively Participants: 199 and 130 3-59 month old children in the (P=0.7).
    [Show full text]
  • ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults
    602 PRACTICE GUIDELINES nature publishing group CME ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults Mark S. Riddle , MD, DrPH1 , H e r b e r t L . D u P o n t , M D 2 and Bradley A. Connor , MD 3 Acute diarrheal infections are a common health problem globally and among both individuals in the United States and traveling to developing world countries. Multiple modalities including antibiotic and non-antibiotic therapies have been used to address these common infections. Information on treatment, prevention, diagnostics, and the consequences of acute diarrhea infection has emerged and helps to inform clinical management. In this ACG Clinical Guideline, the authors present an evidence-based approach to diagnosis, prevention, and treatment of acute diarrhea infection in both US-based and travel settings. Am J Gastroenterol 2016; 111:602–622; doi: 10.1038/ajg.2016.126; published online 12 April 2016 INTRODUCTION supplements previously published Infectious Disease Society of Acute diarrheal infection is a leading cause of outpatient visits, America (IDSA) ( 5 ), and World Gastroenterology Organiza- hospitalizations, and lost quality of life occurring in both domes- tion guidelines ( 6 ). Th is guideline is structured into fi ve sections tic settings and among those traveling abroad. Th e Centers for of clinical focus to include epidemiology and population health, Disease Control and Prevention has estimated 47.8 million cases diagnosis, treatment of acute disease, evaluation of persisting occurring annually in the United States, at an estimated cost symptoms, and prevention. To support the guideline development, upwards of US$150 million to the health-care economy ( 1,2 ).
    [Show full text]
  • Racecadotril for Diarrhoea
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) RACECADOTRIL FOR THE TREATMENT OF ACUTE DIARRHOEA NOT RECOMMENDED Name: What it is Indication Date Decision NICE / SMC generic Decision Status Guidance (trade) last revised Racecadotril intestinal antisecretory symptomatic treatment Nov 2013 Final NICE - No (Hidrasec ®) enkephalinase inhibitor of acute diarrhoea (for Guidance - reduces intestinal up to 7 days) SMC – Not secretion of water and recommended electrolytes HMMC Recommendation: NOT RECOMMENDED for prescribing in adults or children EFFICACY SAFETY • RCTs (with limitations) in adults have • Racecadotril appears to be well tolerated. suggested that racecadotril and loperamide • The Summary of Product Characteristics in are similarly effective in reducing duration of adults reports the most common adverse diarrhoea and number of stools produced. effect with racecadotril as headache and in • Meta-analysis (9 RCTs - with limitations) in children reports uncommon adverse events as children has suggested that racecadotril plus tonsillitis, rash and erythema oral rehydration salt (ORS) solution improves • RCTs in adults have suggested that recovery rates at 2 days, reduces duration of racecadotril has fewer adverse effects, diarrhoea & volume and frequency of stool particularly constipation, than loperamide output more than ORS solution alone or with placebo. • No studies undertaken in the UK setting. COST PATIENT FACTORS • Racecadotril is more expensive than • Prevention or reversal of dehydration is the alternative antimotility agents (current first-line priority in acute diarrhoea and gastroenteritis. options in adults). Cost of 7 days treatment: Most infectious diarrhoea is a self-limited, £8 racecadotril vs £1 loperamide. usually viral illness. Nearly half last less than • Not recommended for use by SMC & AWMSG one day.
    [Show full text]